BioEntrepreneurship - Market Assessment: Great new product or just really cool science?
COURSE DESCRIPTION
This session addresses how early stage biotech financiers determine whether a technology has enough potential commercial value to be considered as an investment opportunity. The complexities and associated risks of developing early stage biotech applications will be discussed. Approaches for evaluating and comparing prospective commercial applications of scientific discoveries will be also reviewed.SPEAKERS
- Kelly Holman, Genesys Capital
- Damian Lamb, Genesys Capital
TOPICS ADDRESSED
- When do you I consider commercializing? How much data do I need?
- The challenges of early stage development assessments:
- Understanding the risk associate with uncertainty
- Estimating your development costs
- How do I assess the value of the opportunity:
- Identifying the competition
- Current products
- Competitive products in development
- Alternative treatments
- Identifying potential market share: reality checks
- Identifying the competition
LEARNING OBJECTIVES
- Realistically assess commercial readiness of the technology
- Forecast and value addressable market opportunity for your technology
- Understand how financiers evaluate early stage biotech opportunities
DATE | TIME | LOCATION
November 13, 2006 - November 13, 20066:00PM - 9:00PM
MaRS Centre
101 College St, Toronto
- Session Presentation - Dial Up Connection (MP4)
- Session Presentation - Broadband Connection (MP4)
- Event blog summary and questions
ABOUT THE SPEAKERS
Kelly Holman Managing Director , Genesys Capital Partners Inc
Kelly is a founder and Managing Director of Genesys Capital and has extensive commercial and technical experience in the biotechnology industry.
Since co-founding Genesys Capital Partners in 2000, Kelly has been actively involved in assisting the NewGen Funds raise over $125 million of venture capital and has been instrumental in deploying over $60 million across 16 investments. He serves on the Board of Directors of Epocal Inc., Insception Biosciences Inc., and Interface Biologics Inc.
Kelly is active in deal origination and company creation and has advised Canada's National Biotechnology Advisory Committee on strategies for financing start-up and early-stage biotechnology companies.
Prior to founding Genesys Capital Partners, Kelly was a Senior Investment Manager with MDS Capital Corp. During his tenure at MDS, he was involved in all stages of investment from start-up and early-stage to mezzanine stage and public company investing.
Previously, Kelly worked in the laboratory of Dr. Peter St George-Hyslop at the University of Toronto where he was a key member of the international research team that discovered several genes responsible for Alzheimer's disease. Kelly holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen's University.
Damian Lamb Managing Director , Genesys Capital Partners Inc
Damian is a founder and Managing Director of Genesys Capital. Damian brings a unique experience base, blending skills in both the commercial and technical side of biotechnology.
Since co-founding Genesys Capital Partners in 2000, Damian has been instrumental in raising over $125 million in venture capital funds, and has been involved in deploying over $60 million in 16 investments. He serves on the Board of DELEX Therapeutics Inc., Ionalytics Corporation and Millenium Biologix Corporation. Damian is the President of the Ottawa Biotechnology Innovation Fund and a director of the Discovery District Biotechnology Fund.
Prior to founding Genesys Capital Partners Inc., Damian was an Investment Manager with MDS Capital Corp. He is a frequently invited speaker at biotechnology industry conferences and has been a judge for the BioNorth Top 10 Canadian Life Sciences Companies contest from 2000 - 2002. Damian graduated from McMaster University, Faculty of Health Sciences, with a MSc in molecular neurobiology. Damian also holds an MBA from Queen's University.
UPCOMING EVENTS
PAST EVENTS
- March 12, 2008
BioEntrepreneurship: What Investors Look For in Life Science Businesses - February 27, 2008
BioEntrepreneurship: Budgeting for life science companies - February 6, 2008
BioEntrepreneurship: Life Science IP - January 16, 2008
BioEntrepreneurship: Navigating the Global Regulatory Path for New Drugs - January 9, 2008
BioEntrepreneurship: Market Assessement for Therapeutics and Medical Devices - December 19, 2007
BioEntrepreneurship: Business Models in Therapeutics and Medical Devices - June 12, 2007
BioEntrepreneurship - Effective Communications: Selling your story to VCs and beyond - May 14, 2007
BioEntrepreneurship - Strategic Financing of Biotech - April 16, 2007
BioEntrepreneurship - VCs and CVs: Managing the people/profit equation - February 12, 2007
BioEntrepreneurship - Clinical Trials Strategy - January 15, 2007
BioEntrepreneurship - Navigating the Global Regulatory Path for New Drugs - December 4, 2006
BioEntrepreneurship - Intellectual Property Strategy - November 13, 2006
BioEntrepreneurship - Market Assessment: Great New Product or Just Really Cool Science? - October 16, 2006
The Business of Biotech
MaRS PICKS
Who's Your City?
MaRS BLOG
- Fail to design = design to fail
- Experience is our obsession: Innovation and the design ecosystem
- Tech in the Soo